Investor Alert

March 9, 2021, 9:28 a.m. EST

Best Biotech Penny Stocks To Watch Before Friday

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Mar 09, 2021 (Penny Stocks via COMTEX) -- Biotech Penny Stocks To Watch Right Now

While penny stocks are well-known for volatility, so too are certain sectors. Possibly no other sector has continued its volatile trend throughout history better than biotechnology. With things like tech stocks, of course, R&D plays a role, and you may have a few updates about upcoming products. But aside from earnings, what other catalysts are frequently in play?

There are so many moving parts when you talk about biotech, and each "move" can become its own catalyst. Additionally, there are countless industry and investor conferences these companies present at. Plenty of interim results also get released. These come ahead of main data sets, which can also act as potential catalysts.

Plus, you've also got sympathy sentiment from the sporadic M&A deals being done. Just think back to the early days of the pandemic. Biotech stocks were some of the biggest names in the market at the time. Whether it was a potential vaccine development or rapid test, sector stocks were red hot.

[Read More] Best Penny Stocks To Watch On Robinhood As Biotech Sector Rebounds

What began as a focus on vaccine stocks has now evolved into a broader focus on biotech. The millions of new traders who jumped into stocks this year became all too familiar with this niche's volatility. Now, we see somewhat of a resurgence in many smaller biotech names.

Further emphasizing this is the momentum that has built up in small-cap stocks, in general. If you look at major benchmark ETFs like the Russell 2000 Small-Cap ( NYSE: IWM ), you'll see how much stronger it has rallied than the SPY or QQQ over the last few days. In this light, are any of these biotech penny stocks on your watch list?

Biotech Penny Stocks To Watch

  1. GT Biopharma Inc. ( NASDAQ: GTBP )

  2. Oragenics Inc. ( NYSE: OGEN )

  3. Auris Medical Holdings ( NASDAQ: EARS )

  4. Caladrius Biosciences Inc. ( NASDAQ: CLBS )

GT Biopharma Inc.

On this list of penny stocks , you'll likely see a few familiar faces, especially if you've been a reader of PennyStocks.com. In line with this, GT Biopharma has been one of the top biotech penny stocks we've discussed for months. GTBP was one of the OTC penny stocks to watch just a few weeks ago. A recent uplisting to the Nasdaq has brought it to a new level of market exposure. The company focuses on immunotherapy. Its lead compound, GTB-3550, has an initial indication for acute myeloid leukemia, myelodysplastic syndrome. Interim data has already been released, showing progress in its current Phase I/II clinical trials.

Not only were no toxicities observed (remember the CRS issue I mentioned above with other treatments), but significant benefits were observed after treatment with GTB-3550 in the seven patients that have been enrolled & have also completed therapy. An 8th patient has also begun treatment in this trial. However, the underlying focus is on the technology platform GTB-3550 is based on. GT Biopharma has developed what it calls TriKE(TM) therapeutics. It has also been evaluated in ovarian, breast, prostate, pancreatic ductal adenocarcinoma, and lung cancer models.

This week news surfaced showing the platform's versatility. The company announced new data from a preclinical study for its ROR1 TriKE(TM) prostate cancer product candidate.

"We are pleased to report our ROR1 TriKE(TM) has passed this important preclinical milestone and demonstrated effectiveness in promoting redirected and target-specific killing by NK cells. We plan to evaluate the ROR1 TriKE(TM) in additional IND-enabling preclinical studies to transition to a Phase I/II clinical trial," said Anthony J. Cataldo, GT Biopharma's Chairman, and Chief Executive Officer.

Oragenics Inc.

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.